- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Hu-manity.co and IBM Partner for Personal Data Property Rights
Hu-manity.co, the organization developing human rights and corollary sovereign laws in a decentralized manner on blockchains, announced it will use IBM’s Blockchain Platform technology for its global consent ledger. Using IBM’s platform, Hu-manity.co will give people control to manage consent, authorization, and commercial use of their personal information via a permissioned blockchain-based data marketplace.
Consumers can claim their human data rights via Hu-manity.co’s #My31 iPhone and Android app built on IBM Blockchain. Some capabilities include users can choose to share no information with third parties, or they may want to provide consent for use of their medical data for cancer research only. Users can also choose to lease their data to pharmaceutical companies or data aggregators but only upon receiving fair market compensation.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
